Get the Stockscreener App
1.80
7.69%
-0.15
After Hours:
1.79
-0.01
-0.56%
Allogene Therapeutics Inc Stock (ALLO) Latest News
Foresight Diagnostics expands Allogene partnership - BizWest
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - The Manila Times
When Will Allogene Reveal Its CAR T Progress? Key Earnings Date Set - StockTitan
Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia - PR Newswire
Allogene Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise - MSN
Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities (NASDAQ:ALLO) - Seeking Alpha
Allogene Expands Partnership With Foresight Diagnostics To Advance Cema-Cel Development Globally - Nasdaq
Allogene Therapeutics Announces Participation in March Investor Conference - The Manila Times
What Will Allogene Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan
Global Advanced Therapy Medicinal Products Market to Grow Immensely at a CAGR of ~14% by 2032 | DelveInsight - The Malaysian Reserve
Allogene Therapeutics Expands Strategic Collaboration with Foresight Diagnostics for MRD Assay Development in Large B-Cell Lymphoma Treatment - Nasdaq
Can Allogene's $37.3M Diagnostic Partnership Transform Lymphoma Treatment Outcomes? - StockTitan
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model - Seeking Alpha
Allogene Therapeutics (NASDAQ:ALLO) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Allogene stock plunges to 52-week low at $1.33 amid steep annual decline - MSN
Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal year - MSN
Insider Sell: Deborah Messemer Sells Shares of Allogene Therapeu - GuruFocus.com
Allogene therapeutics director Deborah Messemer sells $32,350 in stock - Investing.com
Allogene Therapeutics Director Sells Shares Under Trading Plan - TradingView
Allogene therapeutics director Deborah Messemer sells $32,350 in stock By Investing.com - Investing.com UK
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday - Benzinga
Baird ‘encouraged’ by Allogene CAR-T therapy update - TipRanks
Diffuse Large B-cell Lymphoma Market Expected to rise, 2034 | - openPR
Allogene stock hits 52-week low at $1.76 amid market challenges - Investing.com Nigeria
Allogene leaps on allogeneic CAR-T therapy success - The Pharma Letter
Allogene reports promising results for CAR T therapy in lymphoma - MSN
abrdn plc Invests $776,000 in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics Announces Publication of Durable - GlobeNewswire
Allogene reports promising results for CAR T therapy in lymphoma By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Positive Phase 1 Results for Cema-Cel in Treating Relapsed/Refractory Large B-Cell Lymphoma - Nasdaq
Allogene stock plunges to 52-week low at $1.33 amid steep annual decline By Investing.com - Investing.com South Africa
A stock that deserves closer examination: Allogene Therapeutics Inc (ALLO) - US Post News
Ratio Revelations: Allogene Therapeutics Inc (ALLO)’s Financial Metrics in the Spotlight - The Dwinnex
Earl Martin Douglas Sells 6,404 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Sells $25,215.66 in Stock - MarketBeat
Allogene Therapeutics Falls To US$1.51, But Insiders Sold At Lower Price - Simply Wall St
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN
Allogene Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
Follicular Lymphoma Pipeline 2024: Comprehensive Clinical - openPR
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):